Small Pharmaceuticals
Market Cap
₹16,408 ₹16,408 Cr.
P/E
98.49
PEG
7.30
PEG = P/E ÷ 5yr forward EPS CAGR
5yr forward EPS CAGR thesis · Base case

The thesis comes live if test-kit volume scales within existing capacity and assay commercialization supports demand without material tender or customer delays.

The bull path combines faster kit-volume growth with stronger realization; the bear path reflects volume shortfall, weaker pricing, delayed commercialization and underused capacity.

  • Molbio Diagnostics
  • Poly Medicure
  • Dr. Lal Pathlabs

FAQs on Molbio Diagnostics Ltd. Shareprice

There is not enough historical data for the companies share price.

There is insufficient historical data to gauge this.
Latest PE of Molbio Diagnostics is 104.81

Growth Table

  • Molbio Diagnostics Ltd.
  • Poly Medicure
  • Dr. Lal Pathlabs

Balance Sheet

  • Molbio Diagnostics Ltd.
  • Poly Medicure
  • Dr. Lal Pathlabs

Balance Sheet Snapshot

No data available.

Fund Flow Analysis

  • 1y
  • 3y
  • 5y
  • 10y
  • Increase
  • Decrease
  • Total
No data available.
*Data is as of latest FY end

Profit & Loss

  • Molbio Diagnostics Ltd.
  • Poly Medicure
  • Dr. Lal Pathlabs

Cash Flow

  • Molbio Diagnostics Ltd.
  • Poly Medicure
  • Dr. Lal Pathlabs

Cash Flow Analysis

  • 1y
  • 3y
  • 5y
  • 10y
  • Increase
  • Decrease
  • Total
No data available.

Ratios

= Dominant Factor
  • Molbio Diagnostics Ltd.
  • Poly Medicure
  • Dr. Lal Pathlabs

Quarterly Results

  • Molbio Diagnostics Ltd.
  • Poly Medicure
  • Dr. Lal Pathlabs

Reverse DCF

locked
Cr
locked
5 YEAR
locked 5
10 YEAR
locked 10
20 YEAR
locked 20
Implied Growth Rate over a 5 year period*
Implied Growth Rate over a 10 year period*
Implied Growth Rate over a 20 year period*

FAQs on Molbio Diagnostics Ltd. Financials

Balance sheet of Molbio Diagnostics is strong.
It shouldn't have solvency or liquidity issues.

The net debt of Molbio Diagnostics is decreasing.
Latest net debt of Molbio Diagnostics is -₹321.49 Crs as of Mar-26.
This is less than Mar-25 when it was -₹134.92 Crs.

The profit is oscillating.
The profit of Molbio Diagnostics is ₹29.65 Crs for TTM, ₹167 Crs for Mar 2026 and ₹145 Crs for Mar 2025.

The company seems to be paying a very low dividend.
Investors need to see where the company is allocating its profits.
Molbio Diagnostics latest dividend payout ratio is 0% and 3yr average dividend payout ratio is 0%

Companies resources are allocated to majorly productive assets like Plant & Machinery and unproductive assets like Cash & Short Term Investments

Ideas Dashboard
Results
Timeline
Watchlist
Portfolio
Alerts
Stock Screener
Market
Raw Material
Data feed provided by Accord Fintech